Abstract
Chimeric antigen receptor (CAR)-T therapy has been developed as revolutionary treatment in cancer treatment. It has been clinically proven to be effective and durable towards certain subtypes of blood cancer especially in B-cell leukemia or lymphoma. CARs are synthetic receptor which are designed to redirect T lymphocytes to eliminate cancer cells with a specific antigen on the surface. However, limited therapeutic efficacy and safety concern of CAR-T therapy present as obstacles to its application in both solid and hematological cancer. Hence more research is being conducted to study the mechanism behind therapeutic limitation and how to improve its therapeutic effectiveness. Furthermore, innovative strategies should be investigated to limit its toxicities. This review firstly explains the process of CAR-T therapy and its current milestone. Then the review discusses its current challenges and characterize some reasons for its limited therapeutic applications and strategies to improve its efficacy and safety in clinical settings.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
